A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Ovarian Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 400 (planned)
- Started
- Nov 13, 2025
- Main results expected
- Jan 2029
- Fully finished
- Jan 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Substudy 1, 2, and 3: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) (any grade, Grade >= 3)
Measured over: Up to Approximately 40 Months
Substudy 1, 2, and 3: Number of Participants with TEAEs Leading to Discontinuation
Measured over: Up to Approximately 40 Months
Substudy 1, 2, and 3: Number of Participants with Ocular Adverse Events (AEs) (any grade, Grade >= 2)
Measured over: Up to Approximately 40 Months
Substudy 1, 2, and 3: Overall Response (OR) as Assessed by the Investigator per RECIST v1.1
Measured over: Up to Approximately 40 Months
Substudy 1: Progression free survival (PFS) as Assessed by the Investigator per RECIST v1.1
Measured over: Up to Approximately 40 Months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07059845 · record last updated 2026-10-13 · checked 2026-11-09 15:47 UTC